MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 526430 | Name: MDK-0264

Description:

WARNING: This product is for research use only, not for human or veterinary use.

MDK-0264, also known as B-Raf IN, B-Raf Inhibitor and Tyrosine kinase inhibitor, is a novel potent tyrosine kinase inhibitor (TKI). MDK-0264 has CAS#1021950-26-4. For the convenience of communication, we temporally name it as MDK-0264

Chemical Structure

MDK-0264
MDK-0264
CAS#1021950-26-4

Theoretical Analysis

MedKoo Cat#: 526430

Name: MDK-0264

CAS#: 1021950-26-4

Chemical Formula: C31H31FN6O5

Exact Mass: 586.2340

Molecular Weight: 586.62

Elemental Analysis: C, 63.47; H, 5.33; F, 3.24; N, 14.33; O, 13.64

Price and Availability

Size Price Availability Quantity
Bulk Inquiry
Buy Now
Add to Cart
Related CAS #
No Data
Synonym
Tyrosine kinase inhibitor; MDK-0264; MDK0264; MDK 0264; B-Raf IN, B-Raf Inhibitor;
IUPAC/Chemical Name
1,1-Cyclopropanedicarboxamide, N-(4-fluorophenyl)-N'-[4-[[2-[[[2-(4-morpholinyl)ethyl]amino]carbonyl]-1H-pyrrolo[2,3-b]pyridin-4-yl]oxy]phenyl]-
InChi Key
PKOVTRMHYNEBDU-UHFFFAOYSA-N
InChi Code
InChI=1S/C31H31FN6O5/c32-20-1-3-21(4-2-20)35-29(40)31(10-11-31)30(41)36-22-5-7-23(8-6-22)43-26-9-12-33-27-24(26)19-25(37-27)28(39)34-13-14-38-15-17-42-18-16-38/h1-9,12,19H,10-11,13-18H2,(H,33,37)(H,34,39)(H,35,40)(H,36,41)
SMILES Code
C1CC1(C(=O)NC2=CC=C(C=C2)OC3=C4C=C(NC4=NC=C3)C(=O)NCCN5CCOCC5)C(=O)NC6=CC=C(C=C6)F
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info
Biological target:
MDK-0264, also known as B-Raf IN, B-Raf Inhibitor and Tyrosine kinase inhibitor, is a novel potent tyrosine kinase inhibitor (TKI).
In vitro activity:
TBD
In vivo activity:
TBD
Solvent mg/mL mM
Solubility
DMSO 46.0 78.41
Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.

Preparing Stock Solutions

The following data is based on the product molecular weight 586.62 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
TBD
In vitro protocol:
TBD
In vivo protocol:
TBD
1: Xu J, Liu X, Yang S, Zhang X, Shi Y. Clinical response to apatinib monotherapy in advanced non-small cell lung cancer. Asia Pac J Clin Oncol. 2017 Dec 15. doi: 10.1111/ajco.12834. [Epub ahead of print] PubMed PMID: 29243413. 2: Jamroziak K, Szymczyk A, Hus M, Wojciechowska M, Knopinska-Posłuszny W, Hołojda J, Hałaburda K, Warzocha K, Iskierka-Jażdżewska E. Hodgkin's variant of Richter's transformation during ibrutinib therapy in a series of CLL patients; the Polish Adult Leukemia Group report (PALG). Eur J Haematol. 2017 Dec 15. doi: 10.1111/ejh.13016. [Epub ahead of print] PubMed PMID: 29243346. 3: Lussana F, Intermesoli T, Stefanoni P, Rambaldi A. Mechanisms of Resistance to Targeted Therapies in Chronic Myeloid Leukemia. Handb Exp Pharmacol. 2017 Dec 15. doi: 10.1007/164_2017_81. [Epub ahead of print] PubMed PMID: 29242991. 4: Richardson DL, Sill MW, Coleman RL, Sood AK, Pearl ML, Kehoe SM, Carney ME, Hanjani P, Van Le L, Zhou XC, Alvarez Secord A, Gray HJ, Landrum LM, Lankes HA, Hu W, Aghajanian C. Paclitaxel With and Without Pazopanib for Persistent or Recurrent Ovarian Cancer: A Randomized Clinical Trial. JAMA Oncol. 2017 Dec 14. doi: 10.1001/jamaoncol.2017.4218. [Epub ahead of print] PubMed PMID: 29242937. 5: Odogwu L, Mathieu L, Goldberg KB, Blumenthal GM, Larkins E, Fiero MH, Rodriguez L, Bijwaard K, Lee EY, Philip R, Fan I, Donoghue M, Keegan P, McKee A, Pazdur R. FDA Benefit-Risk Assessment of Osimertinib for the Treatment of Metastatic Non-Small Cell Lung Cancer Harboring Epidermal Growth Factor Receptor T790M Mutation. Oncologist. 2017 Dec 14. pii: theoncologist.2017-0425. doi: 10.1634/theoncologist.2017-0425. [Epub ahead of print] PubMed PMID: 29242281. 6: Montone R, Romanelli MG, Baruzzi A, Ferrarini F, Liboi E, Lievens PM. Mutant FGFR3 associated with SADDAN disease causes cytoskeleton disorganization through PLCγ1/Src-mediated paxillin hyperphosphorylation. Int J Biochem Cell Biol. 2017 Dec 11. pii: S1357-2725(17)30314-X. doi: 10.1016/j.biocel.2017.12.008. [Epub ahead of print] PubMed PMID: 29242050. 7: Wang M, Rule S, Zinzani PL, Goy A, Casasnovas O, Smith SD, Damaj G, Doorduijn J, Lamy T, Morschhauser F, Panizo C, Shah B, Davies A, Eek R, Dupuis J, Jacobsen E, Kater AP, Le Gouill S, Oberic L, Robak T, Covey T, Dua R, Hamdy A, Huang X, Izumi R, Patel P, Rothbaum W, Slatter JG, Jurczak W. Acalabrutinib in relapsed or refractory mantle cell lymphoma (ACE-LY-004): a single-arm, multicentre, phase 2 trial. Lancet. 2017 Dec 11. pii: S0140-6736(17)33108-2. doi: 10.1016/S0140-6736(17)33108-2. [Epub ahead of print] PubMed PMID: 29241979. 8: Yoo S, Kim MY, Cho JY. Syk and Src-targeted anti-inflammatory activity of aripiprazole, an atypical antipsychotic. Biochem Pharmacol. 2017 Dec 11. pii: S0006-2952(17)30710-4. doi: 10.1016/j.bcp.2017.12.006. [Epub ahead of print] PubMed PMID: 29241811. 9: von Moos R, Koeberle D, Schacher S, Hayoz S, Winterhalder RC, Roth A, Bodoky G, Samaras P, Berger MD, Rauch D, Saletti P, Plasswilm L, Zwahlen D, Meier UR, Yan P, Izzo P, Klingbiel D, Bärtschi D, Zaugg K; Swiss Group for Clinical Cancer Research (SAKK). Neoadjuvant radiotherapy combined with capecitabine and sorafenib in patients with advanced KRAS-mutated rectal cancer: A phase I/II trial (SAKK 41/08). Eur J Cancer. 2017 Dec 11;89:82-89. doi: 10.1016/j.ejca.2017.11.005. [Epub ahead of print] PubMed PMID: 29241084. 10: Verbiest A, Couchy G, Job S, Zucman-Rossi J, Caruana L, Lerut E, Oyen R, de Reyniès A, Laguerre B, Rioux-Leclercq N, Wozniak A, Joniau S, Van Poppel H, Van Den Eynde K, Beuselinck B. Molecular Subtypes of Clear Cell Renal Cell Carcinoma Are Associated With Outcome During Pazopanib Therapy in the Metastatic Setting. Clin Genitourin Cancer. 2017 Nov 7. pii: S1558-7673(17)30333-6. doi: 10.1016/j.clgc.2017.10.017. [Epub ahead of print] PubMed PMID: 29239846. 11: Nitulescu II, Meyer SC, Wen QJ, Crispino JD, Lemieux ME, Levine RL, Pelish HE, Shair MD. Mediator Kinase Phosphorylation of STAT1 S727 Promotes Growth of Neoplasms With JAK-STAT Activation. EBioMedicine. 2017 Nov 21. pii: S2352-3964(17)30456-5. doi: 10.1016/j.ebiom.2017.11.013. [Epub ahead of print] PubMed PMID: 29239838. 12: Krcek R, Latzer P, Adamietz IA, Bühler H, Theiss C. Influence of vascular endothelial growth factor and radiation on gap junctional intercellular communication in glioblastoma multiforme cell lines. Neural Regen Res. 2017 Nov;12(11):1816-1822. doi: 10.4103/1673-5374.219030. PubMed PMID: 29239327. 13: Moirano SJ, Lima SF, Hume KR, Brodsky EM. Association of prognostic features and treatment on survival time of dogs with systemic mastocytosis: A retrospective analysis of 40 dogs. Vet Comp Oncol. 2017 Dec 14. doi: 10.1111/vco.12373. [Epub ahead of print] PubMed PMID: 29239110. 14: Zhao H, Cao J, Chang J, Zhang Z, Yang L, Wang J, Cantarini M, Zhang L. Pharmacokinetics of Osimertinib in Chinese Patients With Advanced NSCLC: A Phase 1 Study. J Clin Pharmacol. 2017 Dec 14. doi: 10.1002/jcph.1042. [Epub ahead of print] PubMed PMID: 29239002. 15: Li H, Tong CW, Leung Y, Wong MH, To KK, Leung KS. Identification of Clinically Approved Drugs Indacaterol and Canagliflozin for Repurposing to Treat Epidermal Growth Factor Tyrosine Kinase Inhibitor-Resistant Lung Cancer. Front Oncol. 2017 Nov 29;7:288. doi: 10.3389/fonc.2017.00288. eCollection 2017. PubMed PMID: 29238696; PubMed Central PMCID: PMC5712561. 16: Boaz RJ, Vig T, Manojkumar R, Devasia A. Incision site metastasis: Adding insult to injury. J Cancer Res Ther. 2017 Oct-Dec;13(6):1068-1069. doi: 10.4103/0973-1482.180679. PubMed PMID: 29237981. 17: Magnaghi P, Salom B, Cozzi L, Amboldi N, Ballinari D, Tamborini E, Gasparri F, Montagnoli A, Raddrizzani L, Somaschini A, Bosotti R, Orrenius C, Bozzi F, Pilotti S, Galvani A, Sommer J, Stacchiotti S, Isacchi A. Afatinib is a new therapeutic approach in chordoma with a unique ability to target EGFR and Brachyury. Mol Cancer Ther. 2017 Dec 13. pii: molcanther.0324.2017. doi: 10.1158/1535-7163.MCT-17-0324. [Epub ahead of print] PubMed PMID: 29237806. 18: Ai J, Chen Y, Peng X, Ji Y, Xi Y, Shen Y, Yang X, Su Y, Sun YM, Gao Y, Ma Y, Xiong B, Shen J, Ding J, Geng M. Preclinical evaluation of SCC244 (Glumetinib), a novel, potent and highly selective inhibitor of c-Met in MET-dependent cancer models. Mol Cancer Ther. 2017 Dec 13. pii: molcanther.0368.2017. doi: 10.1158/1535-7163.MCT-17-0368. [Epub ahead of print] PubMed PMID: 29237805. 19: Smith KM, Fagan PC, Pomari E, Germano G, Frasson C, Walsh C, Silverman IM, Bonvini P, Li G. Anti-Tumor Activity of Entrectinib, a Pan-TRK, ROS1 and ALK Inhibitor, in ETV6-NTRK3-Positive Acute Myeloid Leukemia. Mol Cancer Ther. 2017 Dec 13. pii: molcanther.0419.2017. doi: 10.1158/1535-7163.MCT-17-0419. [Epub ahead of print] PubMed PMID: 29237803. 20: Yang CJ, Tsai MJ, Hung JY, Lee MH, Tsai YM, Tsai YC, Hsu JF, Liu TC, Huang MS, Chong IW. The clinical efficacy of Afatinib 30 mg daily as starting dose may not be inferior to Afatinib 40 mg daily in patients with stage IV lung Adenocarcinoma harboring exon 19 or exon 21 mutations. BMC Pharmacol Toxicol. 2017 Dec 13;18(1):82. doi: 10.1186/s40360-017-0190-1. PubMed PMID: 29237484.

View History

Trigonelline

Trigonelline